{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:40:40Z","timestamp":1794451240510,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"FHU InovPain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02428-6","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:54:01Z","timestamp":1785340441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and na\u00efve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry"],"prefix":"10.1186","volume":"27","author":[{"given":"S.","family":"Ferrao-Malheiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jiacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lanteri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"2428_CR1","doi-asserted-by":"publisher","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14(6):338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1. PMID: 29691490","DOI":"10.1038\/s41582-018-0003-1"},{"key":"2428_CR2","doi-asserted-by":"publisher","unstructured":"Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2024) CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Handb Clin Neurol 199:107\u2013124. https:\/\/doi.org\/10.1016\/B978-0-12-823357-3.00024-0. PMID: 38307640","DOI":"10.1016\/B978-0-12-823357-3.00024-0"},{"issue":"4","key":"2428_CR3","doi-asserted-by":"publisher","first-page":"333102423115936","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P (2023) Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 43(4):3331024231159366. https:\/\/doi.org\/10.1177\/03331024231159366","journal-title":"Cephalalgia"},{"key":"2428_CR4","doi-asserted-by":"publisher","unstructured":"Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43(3):3331024231152169. https:\/\/doi.org\/10.1177\/03331024231152169. PMID: 36786548","DOI":"10.1177\/03331024231152169"},{"issue":"3","key":"2428_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0333102421989247","volume":"41","author":"HC Diener","year":"2021","unstructured":"Diener HC, Ashina M, Durand-Zaleski I, Kurth T, Lant\u00e9ri-Minet M, Lipton RB, Ollendorf DA, Pozo-Rosich P, Tassorelli C, Terwindt G (2021) Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society. Cephalalgia 41(3):279\u2013293 Epub 2021 Jan 20. PMID: 33472427; PMCID: PMC7961634","journal-title":"Cephalalgia"},{"key":"2428_CR6","doi-asserted-by":"publisher","unstructured":"Pozo-Rosich P, van Veelen N, Caronna E, Vaghi G, Torres-Ferrus M, van der Arend BWH, Goadsby PJ, Ashina M, Wang SJ, Diener HC, Tassorelli C, Terwindt GM (2025) Guidelines of the International Headache Society for Real-World Evidence studies in migraine and cluster headache. Cephalalgia 45(3):3331024251318016. https:\/\/doi.org\/10.1177\/03331024251318016. Epub 2025 Mar 17. PMID: 40095946","DOI":"10.1177\/03331024251318016"},{"key":"2428_CR7","doi-asserted-by":"publisher","first-page":"1355877","DOI":"10.3389\/fneur.2024.1355877","volume":"15","author":"P Irimia","year":"2024","unstructured":"Irimia P, Santos-Lasaosa S, Pozo-Rosich P, Leira R, Pascual J, L\u00e1inez JM (2024) Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review. Front Neurol 15:1355877. https:\/\/doi.org\/10.3389\/fneur.2024.1355877PMID: 38523607; PMCID: PMC10959239","journal-title":"Front Neurol"},{"issue":"3","key":"2428_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254 Epub 2020 Feb 19. PMID: 32075406; PMCID: PMC7066477","journal-title":"Cephalalgia"},{"issue":"1","key":"2428_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 21(1):120. https:\/\/doi.org\/10.1186\/s10194-020-01186-3PMID: 33023473; PMCID: PMC7539382","journal-title":"J Headache Pain"},{"key":"2428_CR10","doi-asserted-by":"publisher","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5. PMID: 35716692","DOI":"10.1016\/S1474-4422(22)00185-5"},{"issue":"8","key":"2428_CR11","doi-asserted-by":"publisher","first-page":"e214863","DOI":"10.1212\/WNL.0000000000214863","volume":"106","author":"RH Jensen","year":"2026","unstructured":"Jensen RH, Lundqvist C, Schytz HW, Tassorelli C, Vernieri F, Lanteri-Minet M, Terwindt GM, Blumenfeld A, Tepper SJ, Josiassen MK, Jansson G, Ettrup A, Mittoux A, Lipton RB (2026) Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial. Neurology 106(8):e214863 Epub 2026 Mar 26. PMID: 41886713; PMCID: PMC13035099","journal-title":"Neurology"},{"issue":"1","key":"2428_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12883-023-03204-8","volume":"23","author":"AJ Starling","year":"2023","unstructured":"Starling AJ, Kymes S, Asher D, Soni-Brahmbhatt S, Karnik-Henry M (2023) Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States. BMC Neurol 23(1):158. https:\/\/doi.org\/10.1186\/s12883-023-03204-8PMID: 37081405; PMCID: PMC10116681","journal-title":"BMC Neurol"},{"issue":"5","key":"2428_CR13","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40120-023-00521-5","volume":"12","author":"Y Bader","year":"2023","unstructured":"Bader Y, Suliman R, Harb M, Santos V, Al Qaisi I, Alsaadi T (2023) Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study. Neurol Ther 12(5):1683\u20131693. https:\/\/doi.org\/10.1007\/s40120-023-00521-5Epub 2023 Jul 7. PMID: 37418120; PMCID: PMC10444733","journal-title":"Neurol Ther"},{"issue":"1","key":"2428_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s10194-024-01764-9","volume":"25","author":"C Argoff","year":"2024","unstructured":"Argoff C, Herzog SP, Smith RM, Kotak SV, Sopina L, Saltarska Y, Soni-Brahmbhatt S, Khan FA (2024) Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study. J Headache Pain 25(1):65. https:\/\/doi.org\/10.1186\/s10194-024-01764-9PMID: 38664605; PMCID: PMC11044317","journal-title":"J Headache Pain"},{"issue":"1","key":"2428_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-024-01788-1","volume":"25","author":"A Scheffler","year":"2024","unstructured":"Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, Nsaka M, Lindner D, Naegel S, Burow P, Fleischmann R, Holle D (2024) Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany. J Headache Pain 25(1):79. https:\/\/doi.org\/10.1186\/s10194-024-01788-1PMID: 38755541; PMCID: PMC11097519","journal-title":"J Headache Pain"},{"key":"2428_CR16","doi-asserted-by":"publisher","unstructured":"Zhao YJ, Ong JJY, Sonu SK, Dang J, Ng CC, Herr KJ, Bose R, Jion YI (2024 Jul-Aug) A real-world prospective observational study of eptinezumab in Asian patients with migraine. Headache 64(7):810\u2013824. https:\/\/doi.org\/10.1111\/head.14737 Epub 2024 May 24. PMID: 38785386","DOI":"10.1111\/head.14737"},{"key":"2428_CR17","doi-asserted-by":"publisher","unstructured":"Triller P, Blessing VN, Overeem LH, Fitzek MP, Hong JB, Lange KS, Reuter U, Raffaelli B (2024) Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study. Cephalalgia 44(10):3331024241288875. https:\/\/doi.org\/10.1177\/03331024241288875. PMID: 39469839","DOI":"10.1177\/03331024241288875"},{"issue":"7","key":"2428_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/brainsci14070672","volume":"14","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Orlando B, Egeo G, d\u2019Onofrio F, Doretti A, Messina S, Autunno M, Messina R, Filippi M, Fiorentini G, Rotondi C, Bonassi S, Aurilia C (2024) Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study. Brain Sci 14(7):672. https:\/\/doi.org\/10.3390\/brainsci14070672PMID: 39061413; PMCID: PMC11275165","journal-title":"Brain Sci"},{"issue":"6","key":"2428_CR19","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00415-025-13095-z","volume":"272","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Aurilia C, Egeo G, Doretti A, d\u2019Onofrio F, Scatena P, Rinalduzzi S, Vinciguerra L, Sansone M, Vecchio R, Drago V, Viticchi G, Bartolini M, Ranieri A, Bandettini di Poggio M, Baldisseri F, Mascarella D, Brusaferri F, Caputi L, Messina S, Autunno M, Valenza A, Orlando B, Distefano M, Borrello L, Pistoia F, Camarda C, Saporito G, Querzola G, Torelli P, Salerno A, Gragnani F, Petolicchio B, Carnevale A, Messina R, Filippi M, Tavani S, Fiorentini G, Bonassi S, Cevoli S, Mannocci A (2025) Italian Migraine Registry (I-GRAINE) study group. A 24-week prospective, multicenter, real-world study on eptinezumab\u2019s effectiveness and safety in migraine prevention (EMBRACE II). J Neurol 272(6):382. https:\/\/doi.org\/10.1007\/s00415-025-13095-zPMID: 40332560; PMCID: PMC12058817","journal-title":"J Neurol"},{"issue":"1","key":"2428_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s10194-025-02180-3","volume":"26","author":"AP Andreou","year":"2025","unstructured":"Andreou AP, Hill B, Al-Rawi R, Murphy M, Soares I, Briscoe J, Kilner R, Lambru G (2025) A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience. J Headache Pain 26(1):235. https:\/\/doi.org\/10.1186\/s10194-025-02180-3PMID: 41168777; PMCID: PMC12573807","journal-title":"J Headache Pain"},{"issue":"1","key":"2428_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s10194-025-02227-5","volume":"26","author":"FA Khan","year":"2025","unstructured":"Khan FA, Herzog SP, Smith RM, Buse DC, Soni-Brahmbhatt S, Awad SF, Grossman SW, Asher D, Patel F, Argoff C (2025) Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine. J Headache Pain 26(1):291. https:\/\/doi.org\/10.1186\/s10194-025-02227-5PMID: 41299232; PMCID: PMC12750955","journal-title":"J Headache Pain"},{"issue":"1","key":"2428_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s10194-025-02165-2","volume":"26","author":"C Argoff","year":"2025","unstructured":"Argoff C, Khan FA, Herzog SP, Smith RM, Soni-Brahmbhatt S, Asher D, Awad SF, Grossman SW, Patel F, Buse DC (2025) Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog. J Headache Pain 26(1):274. https:\/\/doi.org\/10.1186\/s10194-025-02165-2PMID: 41310425; PMCID: PMC12659521","journal-title":"J Headache Pain"},{"issue":"1","key":"2428_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/head.70015","volume":"66","author":"L Gunasekera","year":"2026","unstructured":"Gunasekera L, Cheng S, Foster E, Sivathamboo S, O\u2019Brien T, Butzkueven H, Kulkarni J, Hutton E (2026) A retrospective audit of the real-world safety and effectiveness profile of eptinezumab for treatment-resistant chronic migraine in Australia. Headache 66(1):108\u2013117. https:\/\/doi.org\/10.1111\/head.70015Epub 2025 Dec 2. PMID: 41331996; PMCID: PMC12849520","journal-title":"Headache"},{"issue":"24","key":"2428_CR24","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.3390\/jcm14248793","volume":"14","author":"AA Argyriou","year":"2025","unstructured":"Argyriou AA, Dermitzakis EV, Chondrogianni M, Foska A, Rikos D, Soldatos P, Vikelis M, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group (2025) Testing the Efficacy of Eptinezumab 100\u00a0mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study Group. J Clin Med 14(24):8793. https:\/\/doi.org\/10.3390\/jcm14248793PMID: 41464695; PMCID: PMC12733432","journal-title":"J Clin Med"},{"issue":"1","key":"2428_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-026-02275-5","volume":"27","author":"EV Dermitzakis","year":"2026","unstructured":"Dermitzakis EV, Argyriou AA, Chondrogianni M, Foska A, Rikos D, Athanasopoulos D, Tsironis C, Soldatos P, Koutsokera M, Tsitsaras N, Litsardopoulos P, Mavraki E, Vikelis M, Greek Research Alliance for the Study of Headache and Pain (GRASP) Study Group (2026) Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group. J Headache Pain 27(1):48. https:\/\/doi.org\/10.1186\/s10194-026-02275-5PMID: 41578184; PMCID: PMC12918022","journal-title":"J Headache Pain"},{"issue":"2","key":"2428_CR26","doi-asserted-by":"publisher","first-page":"333102425141465","DOI":"10.1177\/03331024251414659","volume":"46","author":"LF Iannone","year":"2026","unstructured":"Iannone LF, Piella EM, Montisano DA, Fasano C, Sebastianelli G, Coppola G, Ferrandi D, Lanni C, Prudenzano MP, de Tommaso M, Merlo P, De Cesaris F, Chiarugi A, Munaf\u00f2 A, Pistoia F, Ornello R, Doretti A, Grazzi L, Lo Castro F, De Icco R, Vaghi G, Avino G, Romozzi M, Calabresi P, Battistini S, Rufa A, Albanese M, Trimboli M, Carlucci G, Silvestro M, Russo A, Rainero I, Valente MR, Fofi L, Marcosano M, Geppetti P, Altamura C, Vernieri F, Tassorelli C, Sacco S, Guerzoni S (2026) Italian Headache Registry (RICe) Study Group. Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study). Cephalalgia 46(2):3331024251414659. https:\/\/doi.org\/10.1177\/03331024251414659Epub 2026 Feb 12. PMID: 41684106","journal-title":"Cephalalgia"},{"key":"2428_CR27","doi-asserted-by":"publisher","unstructured":"Moisset X, Demarquay G, de Gaalon S, Roos C, Donnet A, Giraud P, Gu\u00e9gan-Massardier E, Lucas C, Mawet J, Valade D, Corand V, Gollion C, Moreau N, Grangeon L, Lant\u00e9ri-Minet M, Ducros A (2024) Migraine treatment: Position paper of the French Headache Society. Rev Neurol (Paris) 180(10):1087\u20131099. https:\/\/doi.org\/10.1016\/j.neurol.2024.09.008. Epub 2024 Oct 15. PMID: 39406556","DOI":"10.1016\/j.neurol.2024.09.008"},{"issue":"1","key":"2428_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-023-01680-4","volume":"24","author":"M Lanteri-Minet","year":"2023","unstructured":"Lanteri-Minet M, Fabre R, Martin C, Pradat K, Alchaar A, Bozzolo E, Duchene ML, Van Obberghen EK, Donnet A, Fontaine D (2023) One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study. J Headache Pain 24(1):152. https:\/\/doi.org\/10.1186\/s10194-023-01680-4. PMID: 37940860; PMCID: PMC10633983","journal-title":"J Headache Pain"},{"key":"2428_CR29","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1-211. https:\/\/doi.org\/10.1177\/0333102417738202. PMID: 29368949","DOI":"10.1177\/0333102417738202"},{"key":"2428_CR30","doi-asserted-by":"publisher","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361\u2009\u2013\u200970. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x. PMID: 6880820","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2428_CR31","doi-asserted-by":"publisher","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahl\u00f6f CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12(8):963\u2009\u2013\u200974. https:\/\/doi.org\/10.1023\/a:1026119331193. PMID: 14651415","DOI":"10.1023\/a:1026119331193"},{"key":"2428_CR32","doi-asserted-by":"publisher","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84(5):422\u2009\u2013\u200935. https:\/\/doi.org\/10.1016\/S0025-6196(11)60561-2. PMID: 19411439; PMCID: PMC2676125","DOI":"10.1016\/S0025-6196(11)60561-2"},{"key":"2428_CR33","doi-asserted-by":"publisher","unstructured":"EuroQol Group (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9. PMID: 10109801","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"5","key":"2428_CR34","doi-asserted-by":"publisher","first-page":"e16187","DOI":"10.1016\/j.heliyon.2023.e16187","volume":"9","author":"P Yalinay Dikmen","year":"2023","unstructured":"Yalinay Dikmen P, Ozge A, Martelletti P (2023) The use of clinical scales and PROMs in headache disorders and migraine, summarizing their dissemination and operationalization. Heliyon 9(5):e16187. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16187. PMID: 37251845; PMCID: PMC10220237","journal-title":"Heliyon"},{"issue":"7624","key":"2428_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335(7624):806\u2013808. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD. PMID: 17947786; PMCID: PMC2034723","journal-title":"BMJ"},{"issue":"1","key":"2428_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s10194-023-01688-w","volume":"24","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK, Starling AJ (2023) Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain 24(1):155. https:\/\/doi.org\/10.1186\/s10194-023-01688-w. PMID: 37985968; PMCID: PMC10662788","journal-title":"J Headache Pain"},{"key":"2428_CR37","doi-asserted-by":"publisher","first-page":"109183","DOI":"10.1016\/j.clineuro.2025.109183","volume":"258","author":"T Alsaadi","year":"2025","unstructured":"Alsaadi T, Adel F, Alsaffarini K, El Jadam C, Alkhateri A, Pagdato B, Suliman R (2025) Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon. Clin Neurol Neurosurg 258:109183. https:\/\/doi.org\/10.1016\/j.clineuro.2025.109183. Epub 2025 Oct 5. PMID: 41056647","journal-title":"Clin Neurol Neurosurg"},{"key":"2428_CR38","doi-asserted-by":"publisher","unstructured":"Ashina M, Lanteri-Minet M, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B, Pozo-Rosich P (2023) Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study. Cephalalgia 43(5):3331024231170807. https:\/\/doi.org\/10.1177\/03331024231170807. PMID: 37125484","DOI":"10.1177\/03331024231170807"},{"key":"2428_CR39","doi-asserted-by":"publisher","unstructured":"Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22(1):16. https:\/\/doi.org\/10.1186\/s10194-021-01227-5. Erratum in: J Headache Pain. 2021;22(1):46. https:\/\/doi.org\/10.1186\/s10194-021-01253-3. PMID: 33781209; PMCID: PMC8008612","DOI":"10.1186\/s10194-021-01227-5"},{"issue":"2","key":"2428_CR40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/head.70000","volume":"66","author":"B Gerard","year":"2026","unstructured":"Gerard B, Praudel H, Lanteri-Minet M, Van Obberghen E, Rocher-Moreau F, Rousset J, Jacquier U, Leroy S, Delin M (2026) First successful protocol for desensitization to eptinezumab. Headache 66(2):556\u2013559. https:\/\/doi.org\/10.1111\/head.70000. Epub 2025 Dec 19. PMID: 41420316; PMCID: PMC12916455","journal-title":"Headache"},{"key":"2428_CR41","doi-asserted-by":"publisher","unstructured":"Phillip D, Lyngberg A, Jensen R (2007) Assessment of headache diagnosis. A comparative population study of a clinical interview with a diagnostic headache diary. Cephalalgia 27(1):1\u20138. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01239.x. PMID: 17212676","DOI":"10.1111\/j.1468-2982.2007.01239.x"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02428-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:05:44Z","timestamp":1785452744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2428"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02428-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This observational study did not require approval from the ethics committee. It was conducted as part of the FHU InovPain registry clinical research program, which received authorization from the French National Commission on Informatics and Liberty (Commission Nationale de l\u2019Informatique et des Libert\u00e9s; CNIL; CIL register no. 278, dated 11\/09\/2017). Patients were included only after providing written informed consent allowing their data recorded in the FHU InovPain registry database to be used for clinical research purposes.","order":1,"name":"Ethics","label":"Ethic approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SFM has no conflict of interest.RF had no conflict of interest.TJ had no conflict of interest.MLM received personal fees for consultancy activities from: Abbvie\/Allergan, Amgen, Eli Lilly, IPSEN, Lundbeck, Medtronic, Novartis, Orion Pharma, Perfood, Pfizer, Reckitt-Benckiser, Savia, Bioelectronics, Teva, UPSA.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"193"}}